Lars Fruergaard Jørgensen might not be a household name, but his company’s drug is. And its success has thrust him — reluctantly — into the limelight.
Lars Fruergaard Jørgensen is a CEO who didn't want to be CEO but under his tenure Novo Nordisk, which makes Ozempic, has achieved tremendous economic growth with an annual turnover of €38.9 billion in 2024 and a profit of €13.
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback